Clinical potential in modern medicine of fibrin glues as drug delivery system

Abstract

In an attempt to achieve greater therapeutic effi ciency of products, especially in the pharmacological area such as drugs in general, the drug delivery system that controls the distribution of substances through macromolecular carriers has been developed with the primary objective of optimizing their delivery to target locations [1]. Records in the scientifi c literature of pioneering controlled drug delivery studies date back to the 1960s at Harvard with the in vivo implantation of a silicone tube that became a drug delivery device, in this case anesthetic gases, at a constant rate of release. [2]. Clinical use was approved in the 1980s and 1990s with the use of microscopic degradable polymer depot Drug Delivery Systems (DDS) but it can be cited that clinical success occurred in the 2000s with nanoscopic products [3]. From this period a rapid evolution occurred and the range of use at both molecular and supramolecular levels was expanded [4]. The clinical use of nanotechnology in health has been a major revolution, with controlled drug release being one of its examples in treating various types of cancer, manufacturing vaccines and treating fungal infections using liposomes as a component [5].